Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ033721
- Development stage
- Unknown
- Lead developer
- I-MAB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TJ033721 is a humanized monoclonal antibody developed by I-Mab Biopharma that targets Claudin 18.2 (CLDN18.2), a tight junction protein frequently overexpressed in various gastrointestinal cancers. The drug is designed to bind specifically to CLDN18.2 on the surface of tumor cells, potentially mediating anti-tumor activity through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced or metastatic solid tumors, with a specific focus on CLDN18.2-positive gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, and pancreatic ductal adenocarcinoma.
- Other names
- TJ033721TJ-033721TJ 033721
02
Targets
Claudin 18.2TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on TJ033721.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ033721.